These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 3003161)

  • 1. Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo.
    Fitzgerald DJ; Doran J; Jackson E; FitzGerald GA
    J Clin Invest; 1986 Feb; 77(2):496-502. PubMed ID: 3003161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonism of prostaglandin-mediated responses in platelets and vascular smooth muscle by 13-azaprostanoic acid analogs. Evidence for selective blockade of thromboxane A2 responses.
    Huzoor-Akbar ; Mukhopadhyay A; Anderson KS; Navran SS; Romstedt K; Miller DD; Feller DR
    Biochem Pharmacol; 1985 Mar; 34(5):641-7. PubMed ID: 3156599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation.
    Li P; Fukuhara M; Diz DI; Ferrario CM; Brosnihan KB
    J Pharmacol Exp Ther; 2000 Jan; 292(1):238-46. PubMed ID: 10604953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity of prostaglandin H2/thromboxane A2 receptors: distinct subtypes mediate vascular smooth muscle contraction and platelet aggregation.
    Furci L; Fitzgerald DJ; Fitzgerald GA
    J Pharmacol Exp Ther; 1991 Jul; 258(1):74-81. PubMed ID: 1830100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 13-Azaprostanoic acid: a specific antagonist of the human blood platelet thromboxane/endoperoxide receptor.
    Le Breton GC; Venton DL; Enke SE; Halushka PV
    Proc Natl Acad Sci U S A; 1979 Aug; 76(8):4097-101. PubMed ID: 291066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 7-[(1R,2S,3S,5R)-6,6-dimethyl-3-(4- iodobenzenesulfonylamino)bicyclo[3.1.1]hept-2-yl]-5(Z)-heptenoic acid: a novel high-affinity radiolabeled antagonist for platelet thromboxane A2/prostaglandin H2 receptors.
    Naka M; Mais DE; Morinelli TA; Hamanaka N; Oatis JE; Halushka PV
    J Pharmacol Exp Ther; 1992 Aug; 262(2):632-7. PubMed ID: 1386885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological characterization of potent, long-acting thromboxane receptor antagonists, SQ 33,261 and SQ 33,552.
    Harris DN; Michel IM; Goldenberg HJ; Hartl KS; Allen GT; Steinbacher TE; Schumacher WA; Han WC; Hall SE; Floyd DM
    J Pharmacol Exp Ther; 1992 Apr; 261(1):131-7. PubMed ID: 1532833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arachidonic acid-induced platelet aggregation is mediated by a thromboxane A2/prostaglandin H2 receptor interaction.
    Parise LV; Venton DL; Le Breton GC
    J Pharmacol Exp Ther; 1984 Jan; 228(1):240-4. PubMed ID: 6319669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenol red is a thromboxane A2/prostaglandin H2 receptor antagonist in canine lingual arteries and human platelets.
    Greenberg SS; Johns A; Kleha J; Xie J; Wang Y; Bianchi J; Conley K
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1352-61. PubMed ID: 8138950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological profile of BMS 180,291: a potent, long-acting, orally active thromboxane A2/prostaglandin endoperoxide receptor antagonist.
    Ogletree ML; Harris DN; Schumacher WA; Webb ML; Misra RN
    J Pharmacol Exp Ther; 1993 Feb; 264(2):570-8. PubMed ID: 8437108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antagonism of thromboxane A2/prostaglandin H2 by 13-azaprostanoic acid prevents platelet deposition to the de-endothelialized rabbit aorta in vivo.
    Le Breton GC; Lipowski JP; Feinberg H; Venton DL; Ho T; Wu KK
    J Pharmacol Exp Ther; 1984 Apr; 229(1):80-4. PubMed ID: 6423815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
    Golino P; Rosolowsky M; Yao SK; McNatt J; De Clerck F; Buja LM; Willerson JT
    J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of thromboxane A2 synthase inhibition, singly or combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary arteries.
    Vandeplassche G; Hemans C; Van de Water A; Xhonneux R; Wouters L; Van Ammel K; De Clerck F
    Circ Res; 1991 Aug; 69(2):313-24. PubMed ID: 1830517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist.
    Ogletree ML; Harris DN; Greenberg R; Haslanger MF; Nakane M
    J Pharmacol Exp Ther; 1985 Aug; 234(2):435-41. PubMed ID: 3926986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cooperative mediation by serotonin S2 and thromboxane A2/prostaglandin H2 receptor activation of cyclic flow variations in dogs with severe coronary artery stenoses.
    Ashton JH; Ogletree ML; Michel IM; Golino P; McNatt JM; Taylor AL; Raheja S; Schmitz J; Buja LM; Campbell WB
    Circulation; 1987 Oct; 76(4):952-9. PubMed ID: 3652429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of ONO-3708, an antagonist of the thromboxane A2/prostaglandin endoperoxide receptor, on platelet aggregation and thrombosis.
    Kondo K; Seo R; Naka M; Kitagawa T; Wakitani K; Sakata M; Kira H; Okegawa T; Kawasaki A
    Eur J Pharmacol; 1989 Apr; 163(2-3):253-61. PubMed ID: 2721574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of SQ 27,427, a thromboxane A2 receptor antagonist, in the human platelet and isolated smooth muscle.
    Harris DN; Greenberg R; Phillips MB; Michel IM; Goldenberg HJ; Haslanger MF; Steinbacher TE
    Eur J Pharmacol; 1984 Aug; 103(1-2):9-18. PubMed ID: 6090180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.
    Golino P; Ambrosio G; Villari B; Ragni M; Focaccio A; Pace L; de Clerk F; Condorelli M; Chiariello M
    J Am Coll Cardiol; 1993 Feb; 21(2):493-501. PubMed ID: 8426016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acetyl glycerylphosphorylcholine aggregates human platelets through two distinct pathways, both dependent on arachidonic acid metabolism.
    Macconi D; Morzenti G; Livio M; Morelli C; Cassina G; Remuzzi G
    Lab Invest; 1985 Feb; 52(2):159-68. PubMed ID: 3155816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "In vitro" and "ex vivo" effects of picotamide, a combined thromboxane A2-synthase inhibitor and -receptor antagonist, on human platelets.
    Berrettini M; De Cunto M; Parise P; Grasselli S; Nenci GG
    Eur J Clin Pharmacol; 1990; 39(5):495-500. PubMed ID: 1963845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.